World's first fully functional 3D-bioprinted pancreas from Polbionica. Produces insulin, glucagon, and C-peptide matching natural human physiology. Stored safely in bioreactor until transplant. Awarded top prize as Polish Product of the Future. Paradigm shift from diabetes symptom management to biological repair. Uses living cells with integrated vascular system for full glycemic regulation. Reduces insulin needs in large animal preclinical tests. Maintains stable blood flow preventing tissue necrosis. Treats type 1 diabetes, pancreatitis complications, and organ shortages. Classified as ATMP by European Medicines Agency. Human implantation possible by 2026. Enables on-demand personalized organ production. Lowers transplant rejection and long-term care costs. Serves as live model for drug testing. Advances global transplantology beyond supply limits.